TIZIANA LIFE SCIENCES PLC Tiziana Life Sciences PLC
("Tiziana" or the "Company")
Warrant Expiry - Reminder
London, 16 January 2017- The Directors of Tiziana Life Sciences plc (AIM: TILS) ("Tiziana" or "the Company") hereby provide an update in respect of the series "B" warrants issued to investors on 18 June 2014 ("Warrants"), in connection with a fundraising by the Company.
The Warrants will lapse at 5.00 p.m. on 28 March 2017. If Warrant holders wish to exercise their Warrants over ordinary shares in the Company prior to the lapsing date, the Company's registrar, Capita Asset Services, will need to have received the necessary exercise notice and payment from the Warrant holder or the Warrant holder's nominee prior to 5.00 p.m. on Tuesday 28 March 2017.
Further information relating to the Warrants, including in relation to how to exercise the Warrants, can be obtained by emailing: info@tizianalifesciences.com or contacting Tiziana via the Company website: www.tizianalifesciences.com. A copy of this notice will be sent to the registered holders of the Warrants shortly.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology.
The Company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently completing phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy and has filed an IND to enroll patients in an exploratory trial in Hepatic Cellular Carcinoma (HCC).
The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.
Tiziana Life Sciences' clinical development teams are working on its Bcl-3 candidate; which has a prominent role in the metastasis of mammary cancers, and has elucidated the mechanism of Bcl-3 action to be a regulator of cancer cell motility and has also determined that Bcl-3 inhibition suppresses cell motility in triple-negative, HER-2-positive PR- and ER-positive breast cancer sub-types, suggesting that Bcl-3 may be a master regulator of this metastatic property not only in aggressive breast cancers, but across the clinical spectrum of breast disease. The Company is preparing the IND package with the intention of progressing to clinical trials early 2017.
For more information go tohttp://www.tizianalifesciences.com
Contacts
Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder | +44 (0)20 7493 2853 |
Cairn Financial Advisers LLP(Nominated adviser) Liam Murray | +44 (0)20 7213 0880 |
Beaufort Securities Limited(Broker) Saif Janjua | +44 (0)20 7382 8300 |
FTI Consulting Simon Conway / Natalie Garland-Collins | +44 (0)20 3727 1000 |
This information is provided by RNS
Tiziana Life Sciences plc published this content on 16 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 16 January 2017 09:35:11 UTC.
Public permalinkhttp://www.publicnow.com/view/A124AFBF26DC002C541A7221F8B9E158F75FCE2D
